Biotech & Pharma

BioMarin fails to find buyer, pulls Roctavian gene therapy off market

22 sec read12 views0 listens

BioMarin failed to find a buyer and has withdrawn its gene therapy Roctavian from the market due to financial pressures and lack of insurer confidence. This highlights the significant risk in high-cost biotech innovations without guaranteed outcomes, crucial for content creators covering healthcare and biotechnology sectors to monitor closely.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & Pharma12 hours ago23 sec read

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, after observing early signs of clinical activity. This expansion aims to gather more data on the drug's efficacy and safety, particularly for pat...

Ali Nemati

Biotech & Pharma12 hours ago29 sec read

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Cindy Cheng, PhD, will discuss the development of dual-payload antibody-drug conjugates (dp-ADCs) to enhance efficacy and overcome drug resistance in cancer treatments. This innovation is crucial for biotech and pharma developers aiming to improve th...

Ali Nemati

Legal & Policy1 day ago32 sec read

A Tribute, A Tactic, Or An Appellate Issue?

A prosecutor's use of hair bows in the Lindsay Clancy murder trial is being scrutinized as a potential tactic that could lead to an appeal, rather than relying solely on evidence. Separately, private equity firm Charlesbank Capital Partners is report...

Ali Nemati